Low-Carbohydrate Diet Impairs the Effect of Glucagon in the Treatment of Insulin-Induced Mild Hypoglycemia: A Randomized Crossover Study
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Objective This study compared the ability of glucagon to restore plasma glucose (PG) after mild hypoglycemia in patients with type 1 diabetes on an isocaloric high-carbohydrate diet (HCD) versus a low-carbohydrate diet (LCD). Research design and methods Ten patients with insulin pump-treated type 1 diabetes randomly completed 1 week of the HCD (≥250 g/day) and 1 week of the LCD (≤50 g/day). After each week, mild hypoglycemia was induced by a subcutaneous insulin bolus in the fasting state. When PG reached 3.9 mmol/L, 100 µg glucagon was given subcutaneously, followed by 500 µg glucagon 2 h later. Results Compared with the HCD, the LCD resulted in lower incremental rises in PG after the first (mean ± SEM: 1.3 ± 0.3 vs. 2.7 ± 0.4 mmol/L, P = 0.002) and second glucagon bolus (4.1 ± 0.2 vs. 5.6 ± 0.5 mmol/L, P = 0.002). No differences were observed between the diets regarding concentrations of insulin, glucagon, and triglycerides. Conclusions The LCD reduces the treatment effect of glucagon on mild hypoglycemia. Carbohydrate intake should be considered when low-dose glucagon is used to correct hypoglycemia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In persons with T2D being treated with alpha-glucosidase inhibitors, who develop hypoglycemia due to use of hypoglycemic agents, oral glucose or lactose-containing foods (dairy products) must be given because alpha-glucosidase inhibitors inhibit the breakdown and absorption of complex carbohydrates and disaccharides.1218–1225”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1222]
Citations
Cites
CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis
Ferrannini, E., Mark, M., & Mayoux, E. (2016) · Diabetes Care · doi:10.2337/dc16-0330 · Cited by 975
The barrier of hypoglycemia in diabetes
Cryer, P. E. (2008) · Diabetes · doi:10.2337/db08-1084 · Cited by 725 · cited 1×
“In individuals with type 1 diabetes, hypoglycemia is a barrier for achieving optimal glycemic control (1).”
BackgroundIntense Exercise Has Unique Effects on Both Insulin Release and Its Roles in Glucoregulation
Marliss, E. B., & Vranic, M. (2002) · Diabetes · doi:10.2337/diabetes.51.2007.s271 · Cited by 390
Partitioning the symptoms of hypoglycaemia using multi-sample confirmatory factor analysis
Deary, I. J., Hepburn, D. A., MacLeod, K. M., & Frier, B. M. (1993) · Diabetologia · doi:10.1007/bf00401150 · Cited by 286
Glucagon physiology and pathophysiology
Sherwood, L. M., Parris, E. E., & Unger, R. H. (1971) · New England Journal of Medicine · doi:10.1056/nejm197108192850806 · Cited by 267 · cited 1×
“with the HCD, which may be caused by an increased intakeof protein combinedwith insulin-independent reduction of the glucose during the LCD (14,15).”
BackgroundHaidar, A., Legault, L., Messier, V., Mitre, T. M., Leroux, C., & Rabasa-Lhoret, R. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70226-8 · Cited by 214 · cited 1×
“However, glucagon treatment cannot eliminate all hypoglycemic events (4).”
BackgroundRussell, S. J., Hillard, M. A., Balliro, C., Magyar, K. L., Selagamsetty, R., Sinha, M., Grennan, K., Mondesir, D., Ekhlaspour, L., Zheng, H., et al. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00489-1 · Cited by 179 · cited 1×
“Low doses of glucagon can effectively treat hypoglycemia (2) and even reduce the risk of hypoglycemia by automated insulin-glucagon delivery systems (3).”
BackgroundFat and carbohydrate balances during adaptation to a high-fat diet
Smith, S. R., de Jonge, L., Zachwieja, J. J., Roy, H. J., Nguyen, T., Rood, J. C., WINDHAUSER, M. M., & Bray, G. A. (2000) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/71.2.450 · Cited by 123
Mini-Dose Glucagon Rescue for Hypoglycemia in Children With Type 1 Diabetes
Haymond, M. W., & Schreiner, B. (2001) · Diabetes Care · doi:10.2337/diacare.24.4.643 · Cited by 112 · cited 1×
“Glucagon may be used as an add-on to insulin in open-loop (18) and closed-loop settings (19).”
BackgroundBischof, M. G., Krššák, M., Krebs, M., Bernroider, E., Stingl, H., Waldhäusl, W. K., & Roden, M. (2001) · Diabetes · doi:10.2337/diabetes.50.2.392 · Cited by 97 · cited 1×
“The LCD has been shown to reduce hepatic glycogen stores in healthy individuals (10) and may be similar in individuals with type 1 diabetes (11).”
Background
Cited by
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Smart, C. E., Annan, F., Higgins, L. A., Jelleryd, E., Lopez, M., & Acerini, C. L. (2018) · Pediatric Diabetes · doi:10.1111/pedi.12738 · Cited by 230
“of hypoglycemia or potentially impair the effect of glucagon in hypoglycemia treatment.(33) It is important to respectfully explore the family’s reasons for”
Glucagon Receptor Signaling and Glucagon Resistance
Janah, L., Kjeldsen, S., Galsgaard, K. D., Winther-Sørensen, M., Stojanovska, E., Pedersen, J., Knop, F. K., Holst, J. J., & Wewer Albrechtsen, N. J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20133314 · Cited by 203
“This indicates that the LCD may have promoted the use of fat over carbohydrates, resulting in increased fat oxidation and ketogenesis [99], supporting the conclusion that glucagon regulates glucose homeostasis mainly through glycogenolysis rather than gluconeogenesis.”
BackgroundSelf-citationSievenpiper, J. L., Chan, C. B., Dworatzek, P. D., Freeze, C., & Williams, S. L. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.10.009 · Cited by 200
The Liver–α-Cell Axis and Type 2 Diabetes
Wewer Albrechtsen, N. J., Pedersen, J., Galsgaard, K. D., Winther-Sørensen, M., Suppli, M. P., Janah, L., Gromada, J., Vilstrup, H., Knop, F. K., & Holst, J. J. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00251 · Cited by 149
Self-citation
Metadata
- Authors
- Ranjan, A., Schmidt, S., Damm-Frydenberg, C., Steineck, I., Clausen, T. R., Holst, J. J., Madsbad, S., & Nørgaard, K.
- Affiliations
- Hvidovre Hospital (DK)
- Department of Endocrinology, Copenhagen University Hospital Hvidovre, Hvidovre, Denmark
- Novo Nordisk (Denmark) (DK)
- University of Copenhagen (DK)
- Corresponding author
- Ranjan, Ajenthen
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2016-10-21
- Volume
- 40
- Issue
- 1
- Pages
- 132-135
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2536220037
- Cited by
- 89
- References
- 19
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 11 · 2023: 9 · 2022: 8 · 2021: 11 · 2020: 13 · 2019: 14 · 2018: 7 · 2017: 2
- FWCI
- 7.72
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- Danish Diabetes Academy
- Danish Diabetes Association
- Poul and Erna Sehested Hansen Foundation
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Physiology (medical) › Diet and metabolism studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- low-carbohydrate diet, glucagon, mild hypoglycemia, type 1 diabetes, high-carbohydrate diet, plasma glucose, insulin-induced hypoglycemia, glucagon response, carbohydrate intake, insulin pump therapy
- MeSH terms
- Adult, Blood Glucose, Diabetes Mellitus, Type 1, Fasting, Female, Glucagon, Humans, Hypoglycemia, Hypoglycemic Agents, Insulin, Insulin Infusion Systems, Male, Middle Aged, Cross-Over Studies, Diet, Carbohydrate-Restricted
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Low-Carbohydrate Diet Impairs the Effect of Glucagon in the Treatment of Insulin-Induced Mild Hypoglycemia: A Randomized Crossover Study. https://app.cochat.ai/papers/10.2337/dc16-1472
- The paper
- Ranjan, A., Schmidt, S., Damm-Frydenberg, C., Steineck, I., Clausen, T. R., Holst, J. J., Madsbad, S., & Nørgaard, K. (2017). Low-Carbohydrate Diet Impairs the Effect of Glucagon in the Treatment of Insulin-Induced Mild Hypoglycemia: A Randomized Crossover Study. Diabetes Care. https://doi.org/10.2337/dc16-1472
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.